Industry White Paper: Contemporary Opportunities and Challenges in Characterizing Crystallinity in Amorphous Solid...

Area of Science:

• Pharmaceutical Sciences
• Analytical Chemistry
• Materials Science

Background:

• Amorphous solid dispersions (ASDs) are crucial for improving drug solubility and bioavailability.
• Ensuring the physical stability and low crystalline content in ASDs is critical for product efficacy.
• Current analytical methods face limitations in detecting trace amounts of crystalline drug substance in ASDs.

Purpose of the Study:

• To provide a perspective on the analytical challenges and limitations in detecting low levels of crystalline drug in ASDs.
• To guide the pharmaceutical industry in developing best practices for ASD characterization.
• To promote consistency in development and registration approaches for quality ASD products.

Main Methods:

• Review of analytical challenges associated with monitoring crystalline drug substance in ASDs.
• Discussion of limitations related to limit tests, analyte spiking, and method robustness.
• Evaluation of the merits and limitations of various analytical techniques (XRPD, NIR, DSC).

Main Results:

• Detection of low crystalline drug levels in ASDs is analytically challenging.
• Various analytical techniques possess distinct advantages and disadvantages for ASD characterization.
• Method robustness and appropriate experimental design are critical for reliable results.

Conclusions:

• Sensitive analytical technologies are essential for guiding ASD development and ensuring product quality.
• Standardized characterization best practices are needed to improve consistency in ASD development and registration.
• A comprehensive analytical toolbox, including XRPD, NIR, and DSC, aids in ASD characterization and quality control.